LEO Pharma
LEO Pharma, founded in 1908 and headquartered in Denmark, is a global leader in medical dermatology, focusing on treatments for psoriasis, eczema, acne, and skin infections, and is majority owned by the LEO Foundation.
Company History
LEO Pharma was founded in 1908 and is headquartered in Denmark. The company has a long history of pioneering treatments in dermatology. Notably, it developed the first Danish drug to be exported. Over the years, LEO Pharma has evolved into a global entity, with operations in multiple countries and a strong focus on medical dermatology.
Focus and Specialization
LEO Pharma is committed to being a global leader in medical dermatology. The company focuses on developing drugs and therapies for the treatment of conditions such as psoriasis, eczema, acne, and skin infections. Additionally, the company has a dedicated division for thrombosis products. Their strong pipeline includes early and late-stage assets tackling underserved dermatological disease areas.
Research and Development
LEO Pharma places a significant emphasis on research and development, allocating 13% of its turnover to R&D efforts. The company is keen on advancing its pipeline through collaborations with academia, biotech, and pharmaceutical companies. This commitment highlights their proactive approach to addressing patient needs and discovering innovative treatments.
Corporate Governance
LEO Pharma operates with a proactive and transparent corporate governance structure. The company is majority-owned by the LEO Foundation, which is one of Denmark’s largest commercial foundations. The foundation also provides philanthropic grants to support international research in skin diseases, underlining their commitment to improving patient care globally.
Sustainability and Corporate Social Responsibility
LEO Pharma is dedicated to operating sustainably and minimizing its environmental impact. The company has a business-driven approach to corporate social responsibility (CSR) and engages in numerous initiatives to support patient organizations and advocate for better healthcare access for individuals with skin diseases. Additionally, LEO Pharma prioritizes transparency in clinical trials and interactions with healthcare professionals.